Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Palisade Bio (PALI) Capital Expenditures (2016 - 2022)

Palisade Bio has reported Capital Expenditures over the past 10 years, most recently at $10000.0 for Q4 2022.

Quarterly Capital Expenditures changed N/A to $10000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $10000.0 through Sep 2024, down 9.09% year-over-year, with the annual reading at $4000.0 for FY2023, 60.0% down from the prior year.
Capital Expenditures was $10000.0 for Q4 2022 at Palisade Bio, up from $1000.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $10000.0 in Q4 2022 and troughed at -$1000.0 in Q3 2020.